The results indicated that in HFD mice, all low-dose SZ-A, high-dose SZ-A, and dapagliflozin interventions significantly improved insulin tolerance, lowered blood lipids and ameliorated liver steatosis and liver fibrosis in HFD mice compared with the intervention of normal saline, where the effect of high-dose SZ-A was better than low-dose SZ-A and dapagliflozin. The gene discussed is INS; the disease is fatty liver disease.